Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Journal
The Lancet Oncology
Journal Volume
18
Journal Issue
10
Pages
1360-1372
Date Issued
2017
Author(s)
Kim S.-B.
Maslyar D.J.
Dent R.
Im S.-A.
Espi? M.
Blau S.
Tan A.R.
Isakoff S.J.
Oliveira M.
Saura C.
Wongchenko M.J.
Kapp A.V.
Chan W.Y.
Singel S.M.
Baselga J.
Kim S.-B.
Lee K.S.
Im S.-A.
Espi? M.
Wang H.-C.
Blau S.
Dent R.
Tan A.
Sohn J.H.
De Laurentiis M.
Estevez L.G.
Romieu G.
Velez M.
Villanueva R.
Conte P.F.
Dakhil S.
Debled M.
Martin A.G.
Hurvitz S.
Kim J.H.
Levy C.
Oliveira M.
Rovira P.S.
Seo J.H.
Valero V.
Vidal G.
Wong A.
Allison M.A.K.
Figlin R.
Chan D.
Chen S.-C.
Chen Y.-H.
Cobleigh M.
De Braud F.
Dirix L.
Hansen V.
Bessard A.H.
Iannotti N.
Isakoff S.
Lawler W.
Monta?o A.
Salkini M.
Seigel L.
on behalf of the, LOTUS investigators, LOTUS investigators
SDGs
Publisher
Lancet Publishing Group
Type
journal article